Skip to main content
Clinical Trials/NCT05943405
NCT05943405
Completed
Not Applicable

The Disease Severity In Patients With Psoriasis

Universitas Sebelas Maret1 site in 1 country33 target enrollmentJune 1, 2022
ConditionsPsoriasis

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Psoriasis
Sponsor
Universitas Sebelas Maret
Enrollment
33
Locations
1
Primary Endpoint
Gamma-Glutamyl Transferase
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

This observational study aims to evaluate new markers to predict disease activity in psoriasis. The main question is SGOT, SGPT, GGT, hs-CRP, and apo B related to disease severity in psoriasis.

Detailed Description

Psoriasis patients who had signed an informed consent were assessed for PASI scores and 5 cc of blood was drawn for GGT, hs-CRP, and apo B examinations. A PASI score is a tool used to measure the severity and extent of psoriasis. PASI is an acronym for Psoriasis Area and Severity Index.

Registry
clinicaltrials.gov
Start Date
June 1, 2022
End Date
December 30, 2022
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Nurhasan Agung Prabowo, MD

Head of Hospital Research Unit

Universitas Sebelas Maret

Eligibility Criteria

Inclusion Criteria

  • Clinical diagnosis of Psoriasis

Exclusion Criteria

  • Heart Failure
  • Diabetes Mellitus
  • Kidney Disease

Outcomes

Primary Outcomes

Gamma-Glutamyl Transferase

Time Frame: only in admission

Gamma-Glutamyl Transferase was check in admission, reference range for adults is 5 to 40 U/L (units per liter)

Apolipoprotein B

Time Frame: only in admission

Apolipoprotein B (ApoB) is the primary apolipoprotein and is the carrier for the following lipids: chylomicrons, low-density lipoprotein ( LDL), very low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), and lipoprotein. Unit used in mg/dL

High-sensitivity c-reactive protein

Time Frame: only in admission

High-sensitivity C-reactive protein (hsCRP) is a marker of inflammation that predicts incident myocardial infarction, stroke, peripheral arterial disease, and sudden cardiac death. Unit used in mg/L

PASI

Time Frame: only in admission

A PASI (The Psoriasis Area and Severity Index) score can range from 0 to 72

Study Sites (1)

Loading locations...

Similar Trials